Dr. Raushan Kurmasheva’s laboratory has been awarded a $400K NCI SBIR Phase II grant titled “Enhanced overall survival in high-risk pediatric tumors using a novel oral small molecule.”

Federal Awarding Agency: NIH/NCI

Project Title: Enhanced overall survival in high-risk pediatric tumors using a novel oral small molecule.

Sub PI: Raushan Kurmasheva, PhD

Start: 9/15/25 End: 9/14/27 Amount: $401,844

Project Summary: The research in this NCI-SBIR phase 2 contract focuses on developing a therapeutic for rare pediatric cancers. The original phase 1 contract was for the development of a novel therapy for rhabdomyosarcoma, a rare, aggressive pediatric cancer with poor outcomes. This contract will allow us to complete IND-enabling studies for our drug candidate and to identify additional pediatric cancers that could be included in a Phase 2 clinical trial.

Since 2004, UT Health San Antonio, Greehey Children’s Cancer Research Institute’s (Greehey CCRI) mission has been to advance scientific knowledge relevant to childhood cancer, contribute to the understanding of its causes, and accelerate the translation of knowledge into novel therapies. Through the discovery, development, and dissemination of new scientific knowledge, Greehey CCRI strives to have a national and global impact on childhood cancer. Our mission consists of three key areas: research, clinical, and education.

Stay connected with the Greehey CCRI on Facebook, Twitter, LinkedIn, and Instagram.